Wednesday, March 23, 2016

Immune Therapeutics’ (IMUN) Lodonal Armors Africa against AIDS

Thought to have originated in Africa, the acquired immunodeficiency syndrome (AIDS) has undoubtedly become a scourge of the continent, particularly south of the Sahara. According to AVERT, the U.K.-based international charity, in sub-Saharan Africa, 24.7 million people, or about 4.7% of the continental population, were living with the human immunodeficiency virus (HIV) in 2013, the last year for which data is available. Over one million of those individuals have died every year since. South Africa, with 5.9 million, has the highest number of infected persons. Swaziland’s HIV infection rate of 27.4% (2013) is the highest worldwide. In Nigeria, although the HIV rate is comparably low (3.2%), this translates into 3.2 million persons because of the country’s huge population. Thus, the recently concluded 90-day bridging trial of HIV-positive patients in Nigeria by Immune Therapeutics, Inc. (OTCQB: IMUN) was most welcome.

In January 2016, on completion of the bridging trial, the company announced it had submitted data to Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC). The company expects that the Nigerian authorities will approve Lodonal™ as a treatment for those with compromised immune systems, such as occurs in HIV infection. The bridging study sought to examine the effectiveness of Lodonal as a treatment to stabilize and improve CD4 count. The parameters of stabilization were set at 10% either side of the mean. A 25% increase in CD4 count, in the infected group over the control group, was set as the target for Lodonal’s effectiveness in improving CD4 cell count.

A CD4 count is a lab test that measures the number of CD4 T lymphocytes (CD4 cells) in a sample of blood. In people with HIV, it is the most important laboratory indicator of how well the immune system is working and the strongest predictor of HIV progression. CD4 cells (often called T-cells or T-helper cells) are a type of white blood cells that play a major role in protecting your body from infection. They send signals to activate your body’s immune response when they detect invasion from viruses or bacteria. The CD4 count of a healthy individual typically ranges from 500 cells per cubic millimeter to 1,200 cells per cubic millimeter. When the count falls below 200 cells per cubic millimeter, it may indicate that a person living with HIV has progressed to stage 3 infection (AIDS).

The progression of an HIV infection typically follows three stages. Acute HIV infection is the first stage. It is characterized by symptoms similar to a very bad attack of influenza and usually occurs some two to four weeks after contraction of the virus. Also referred to as acute retroviral syndrome (ARS) or primary HIV infection, these flu-like symptoms are signs of the body’s natural response to the HIV infection.

After the acute stage of HIV infection, the disease moves into a stage called the clinical latency stage, during which the virus continues to live and reproduce at very low levels but produces no or very mild symptoms. This period is also referred to as the asymptomatic HIV infection or chronic HIV infection stage. AIDS is the third and final stage, when the immune system has been so greatly compromised that the body can no longer ward off opportunistic infections. An individual is also considered to have progressed to AIDS if he or she develops one or more opportunistic illnesses, regardless of the CD4 count. Without treatment, people who progress to AIDS typically survive about three years. If a dangerous opportunistic illness is contracted, life-expectancy without treatment falls to about one year.

Immune Therapeutics, Inc. is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. The company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN), known internationally as Lodonal, and Methionine-Enkephalin (MENK). Both therapies have been decades in the making at institutions such as the Pennsylvania State University Medical School at Hershey, University of Chicago, State University of New York, and Multiple Sclerosis Center at UCSF. These efforts were pioneered by leading immunologists, including Dr. Nicholas Plotnikoff, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, Dr. Jill Smith, Patricia McLaughlin, and Dr. Jaquelyn McCandless.

Learn more by visiting www.immunetherapeutics.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: